

IPR and Innovation

1. [Drug Patent Dispute Emerges as Hurdle to Pacific Trade Deal](#) – Bloomberg

Medical & Regulatory

1. [Clinical trial data should be open to public view](#) – Financial Times
2. [Centre needs to amend D&C Act & Rules to enforce Pharmacy Practice Regulations as per Pharmacy Act](#) - Pharmabiz

Others

1. [Pharma giants voice policy concerns at regional meet](#) – Hindu Business Line

IPR and Innovation

1. [Drug Patent Dispute Emerges as Hurdle to Pacific Trade Deal](#) – Bloomberg
Drug patent rules are shaping up as one of the thorniest issues standing in the way of a massive Asia-Pacific trade deal as talks get under way in Hawaii. The dispute pits the administration of U.S. President Barack Obama and the pharmaceutical industry against poorer countries participating in the Trans-Pacific Partnership, such as Chile, Malaysia, Peru and Vietnam. At issue is a class of drugs called biologics. Developing nations are allied with richer countries like Australia, who don't want to adopt U.S. rules that let drug companies keep confidential clinical data generated to win regulatory approval for such products.

Medical & Regulatory

1. [Clinical trial data should be open to public view](#) – Financial Times
A much needed drive to open the results of clinical trials to public scrutiny is gathering momentum. Last week 85 institutional investors threw their weight behind activists demanding more transparency in pharmaceutical research; this week 50 patient and medical organisations in the US will add their voices to the international AllTrials campaign. At issue is the longstanding failure by researchers, in industry and universities, routinely to release the results of studies in which people are subjected to experimental drugs and other medical interventions. The proportion of trials that remains unpublished is hard to estimate but may be as much as half.
2. [Centre needs to amend D&C Act & Rules to enforce Pharmacy Practice Regulations as per Pharmacy Act](#) - Pharmabiz
For enforcing the Pharmacy Practice Regulations (PPR) 2015, the Drugs & Cosmetics Act and Rules must be amended in its favour by the Union government, says Dr Subhash C Mandal, chairman of the regulatory affairs division of the Indian Pharmaceutical Association (IPA). He was responding to Pharmabiz from Kolkata on the ongoing dispute over carrying out inspections at medical stores by pharmacy inspectors in Kerala. According to him, the

pharmacy inspectors must inspect the places where medicines are dispensed. For this purpose alone, the term 'dispensing' has been clearly defined in the PPR which was approved by the Union government and notified by the Pharmacy Council of India (PCI).

Others

1. [Pharma giants voice policy concerns at regional meet](#) – Hindu Business Line
Chairman of Dr Reddy's Labs K Satish Reddy has said that restrictive policies in the drug sector were impacting the industry in an unhealthy way. Referring to the price control of certain drugs through the Drug Pricing Control Order (DPCO), he said the discretionary policy in cutting down costs of a range of drugs would hurt the industries. Reddy, who is also the Chairman of the Indian Pharmaceutical Alliance (IPA), was addressing the regional meet of the Department of Pharmaceuticals, co-hosted by the Bulk Drug Manufacturers Association (BDMA), on the theme '2015 – The Year of Active Pharmaceutical Ingredients'.